30 April 2012 - Rhenovia in Medical News Today: Rare, Orphan And Neglected Neurodegenerative Diseases - New Research Announced

Mulhouse, France and Cambridge, MA, USA - April 30, 2012

Rhenovia Pharma, a leading biotech company that specializes in biosimulation to discover new drugs for the treatment of neurogenerative, neurological and psychiatric diseases, has decided to expand its expertise to cover rare, orphan and neglected diseases and announced that it is starting drug research programs for Huntington's disease (HD) and Duchenne muscular dystrophy (DMD). 
 


Rhenovia has decided to start building a new biosimulation platform (RHENOMS(TM) STRI) that focuses on modeling the complex interaction between biological mechanisms in the striatum, a key area in the brain that plays a major role in HD, a fatal, rare neurodegenerative disease, which is extremely difficult to treat due to the wide range of symptoms, like involuntary movement disorders, cognitive deficits and psychiatric manifestations.

Please find attached the full article. For further information we invite you to contact us: info@rhenovia.com

Rhenovia in MNT 22mar12.pdf